Scan here or visit
BRILINTATouchPoints.com
• Premature discontinuation increases the risk of MI,
stent thrombosis, and death
• Dyspnea was reported in 14% of patients treated with
BRILINTA and in 8% of patients taking clopidogrel.
Dyspnea resulting from BRILINTA is self-limiting. Rule
out other causes
• BRILINTA is metabolized by CYP3A4/5. Avoid use with
strong CYP3A inhibitors and potent CYP3A inducers.
Avoid simvastatin and lovastatin doses >40 mg
• Monitor digoxin levels with initiation of, or any change in,
BRILINTA therapy
ADVERSE REACTIONS
• The most commonly observed adverse reactions associated
with the use of BRILINTA vs clopidogrel were Total Major
Bleeding (11.6% vs 11.2%) and dyspnea (14% vs 8%)
• In clinical studies, BRILINTA has been shown to increase the
occurrence of Holter-detected bradyarrhythmias. PLATO
excluded patients at increased risk of bradycardic events.
Consider the risks and benefits of treatment
Please see Brief Summary of Prescribing Information,
including Boxed WARNINGS, on the adjacent pages.
BR %1%9Q